#1 Clinical Trials Search in Europe

Deferoxamine Mesilate

Deferoxamine Mesilate, also known as Deferoxamine Mesylate or DFO, is being investigated in several clinical trials for its potential to improve outcomes in patients with various types of stroke, including intracerebral hemorrhage and subarachnoid hemorrhage. This iron-chelating agent is being studied for its ability to reduce brain damage and improve functional outcomes in stroke patients. The trials aim to determine the safety, tolerability, and efficacy of Deferoxamine Mesilate in different dosages and administration methods.

Table of Contents

What is Deferoxamine Mesylate?

Deferoxamine Mesylate, also known as DFO, Desferal, or deferoxamine, is a medication that has been used for over 30 years to remove excess iron from the body[1]. Recently, researchers have been studying its potential benefits in treating various types of stroke and brain hemorrhage[2][3][4][4].

What Conditions Does Deferoxamine Mesylate Treat?

Based on ongoing clinical trials, Deferoxamine Mesylate is being investigated as a potential treatment for several conditions related to stroke and brain hemorrhage:

  • Intracerebral Hemorrhage (ICH): This is a type of stroke caused by bleeding within the brain tissue[1][2].
  • Subarachnoid Hemorrhage (SAH): This is bleeding that occurs in the space between the brain and the surrounding membrane[3].
  • Acute Ischemic Stroke: This type of stroke occurs when blood flow to part of the brain is blocked[4].

How Does Deferoxamine Mesylate Work?

Deferoxamine Mesylate works as an iron chelator, which means it binds to excess iron in the body and helps remove it[1]. In the context of stroke and brain hemorrhage, researchers believe that Deferoxamine Mesylate may help in several ways:

  • Reducing iron accumulation in the brain after bleeding, which may contribute to brain injury[1].
  • Improving cerebrovascular regulation, which refers to how well blood flow in the brain is controlled[3].
  • Potentially protecting brain cells from damage caused by lack of oxygen (ischemia)[3].

How is Deferoxamine Mesylate Administered?

In the clinical trials, Deferoxamine Mesylate is typically administered through intravenous (IV) infusion. The dosage and duration of treatment vary depending on the specific study:

  • In some trials, it’s given at a dose of 32 mg/kg/day for 3 consecutive days[1][4].
  • Other studies use different dosages, ranging from 7 mg/kg to 125 mg/kg per day[2].
  • Some trials administer it for up to 5 consecutive days[3].

Ongoing Research and Clinical Trials

Several clinical trials are currently investigating the effectiveness of Deferoxamine Mesylate for various stroke-related conditions:

  • The iDEF Trial is studying its use in intracerebral hemorrhage[1].
  • A study is examining its potential to prevent delayed cerebral ischemia after subarachnoid hemorrhage[3].
  • The ACT-GLOBAL trial is investigating its use in combination with another drug called colchicine for intracerebral hemorrhage[4].

Potential Benefits of Deferoxamine Mesylate

While research is still ongoing, scientists hope that Deferoxamine Mesylate may provide several benefits for stroke patients:

  • Improved functional outcomes after stroke, as measured by scales like the modified Rankin Scale (mRS)[1][4].
  • Reduced brain damage and better recovery after intracerebral hemorrhage[1][2].
  • Prevention of delayed cerebral ischemia after subarachnoid hemorrhage[3].

Possible Side Effects and Safety Concerns

As with any medication, Deferoxamine Mesylate may have side effects. The clinical trials are carefully monitoring for any adverse events, including:

  • Allergic reactions during infusion[4].
  • Hypotension (low blood pressure)[4].
  • Visual or auditory changes[4].
  • Respiratory complications[4].

It’s important to note that these potential side effects are being closely monitored in the clinical trials, and the safety of the drug is a key focus of the research[1][2][3][4].

Aspect Details
Drug Name Deferoxamine Mesilate (also known as Deferoxamine Mesylate or DFO)
Mechanism Iron-chelating agent, potentially reducing brain damage by removing excess iron
Stroke Types Studied Intracerebral Hemorrhage (ICH), Subarachnoid Hemorrhage (SAH)
Administration Intravenous infusion, typically 32 mg/kg/day for 3-5 consecutive days
Primary Outcomes Functional neurological status (modified Rankin Scale), safety, tolerability
Secondary Outcomes Brain swelling, iron levels, quality of life, length of hospital stay
Trial Designs Phase II, randomized, placebo-controlled, adaptive platform trials
Potential Benefits Improved functional outcomes, reduced brain damage, decreased disability
Monitored Side Effects Allergic reactions, blood pressure changes, visual/auditory changes
Current Status Ongoing clinical trials to determine efficacy and optimal dosing

FAQ

  • What is Deferoxamine Mesilate and how does it work in stroke treatment? Deferoxamine Mesilate is an iron-chelating agent that has been used for over 30 years to remove excess iron from the body. In stroke treatment, it is believed to work by reducing iron accumulation in the brain after bleeding, which may help minimize brain damage and improve patient outcomes.
  • What types of stroke are being studied with Deferoxamine Mesilate? Clinical trials are investigating Deferoxamine Mesilate for various types of stroke, including intracerebral hemorrhage (bleeding in the brain) and subarachnoid hemorrhage (bleeding in the space surrounding the brain).
  • How is Deferoxamine Mesilate administered in these trials? In most trials, Deferoxamine Mesilate is administered intravenously (through a vein). The dosage and duration vary between studies, but common regimens include 32 mg/kg/day for 3 consecutive days or up to 5 days.
  • What are the main outcomes being measured in these trials? The main outcomes being measured include functional neurological status (often using the modified Rankin Scale), safety and tolerability of the drug, and various measures of brain function and recovery. Some trials also look at the drug's effect on brain swelling and iron levels.
  • Are there any known side effects of Deferoxamine Mesilate in stroke patients? While Deferoxamine Mesilate has been used safely for other conditions, the trials are closely monitoring for potential side effects in stroke patients. These may include allergic reactions, changes in blood pressure, and effects on vision or hearing. The studies are designed to carefully assess the safety profile in this specific patient population.

Ongoing Clinical Trials on Deferoxamine Mesilate

  • Study on Deferoxamine to Improve Hypoxia Response in Type 1 Diabetes Patients

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on Deferoxamine for Patients with Aneurysmal Subarachnoid Hemorrhage

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Imaging Lung Aspergillosis Using Gallium-68 Deferoxamine for Patients with Pulmonary Aspergillosis

    Recruiting

    2 1 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Deferoxamine Mesilate (DFO): An iron-chelating agent used to remove excess iron from the body, being studied for its potential to reduce brain damage in stroke patients.
  • Intracerebral Hemorrhage (ICH): A type of stroke caused by bleeding within the brain tissue, often leading to severe disability or death.
  • Subarachnoid Hemorrhage (SAH): A type of stroke caused by bleeding in the space surrounding the brain, often resulting from a ruptured aneurysm.
  • Modified Rankin Scale (mRS): A scale from 0 to 6 used to measure the degree of disability in stroke patients, with lower scores indicating better outcomes.
  • Perihaematomal Oedema (PHE): Swelling that occurs around the area of bleeding in the brain following a hemorrhagic stroke.
  • Iron Chelation: The process of binding and removing excess iron from the body, which may help reduce damage caused by iron toxicity in stroke patients.
  • Endovascular Thrombectomy: A minimally invasive procedure to remove a blood clot from a brain artery in ischemic stroke patients.
  • National Institutes of Health Stroke Scale (NIHSS): A tool used to objectively quantify the impairment caused by a stroke, with scores ranging from 0 to 42.
  • Adaptive Platform Trial: A flexible trial design that allows for multiple treatments to be studied simultaneously and for new treatments to be added or removed as the trial progresses.
  • Functional Outcome: The degree of a patient's ability to perform daily activities and live independently after a stroke, often measured using scales like the mRS.

References

  1. https://clinicaltrials.gov/study/NCT02175225
  2. https://clinicaltrials.gov/study/NCT00598572
  3. https://clinicaltrials.gov/study/NCT02216513
  4. https://clinicaltrials.gov/study/NCT06352632